Pharmaceutical intermediates
Ritlecitinib tosylate Intermediates
4 pharmaceutical intermediates for Ritlecitinib tosylate. Indication: Alopecia Areata.
About Ritlecitinib tosylate
- Originator
- Fizer Inc
- Indication
- Alopecia Areata
- Approved Date
- 06/23/2023
- NCE Patent
- 06/23/2028
- DS/DP
- 12/03/2034
Available intermediates
4 intermediates currently listed for Ritlecitinib tosylate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| benzyl 5-amino-2-methylpiperidine-1-carboxylate | 1823290-56-7 | / | / |
| 5-AMino-2-Methyl-piperidine-1-carboxylic acid benzyl ester | 1207947-49-6 | / | / |
| benzyl(2S,5R)-5-amino-2-methylpiperidine-1-carboxylate | 1207853-23-3 | / | / |
| (R)-(-)-N-(3,5-DINITROBENZOYL)-ALPHA-PHENYLGLYCINE | 74927-72-3 | / | / |
Other programs under R
Building toward Ritlecitinib tosylate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →